Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Niraj Tolia · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $723,116 — Malaria is caused by eukaryotic parasites that display distinct surface antigens during three independent stages of the life cycle: 1) initial infection caused by the pre-erythrocytic stage, 2) clinical symptoms as a result of the blood stage, and 3) transmission by the mosquito stage. While both T-…
Andrea Marzi · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $222,715 — 1. Intranasal single-dose vaccination with VSV-based COVID-19 vaccines protects rodents from disease We designed, cloned, and recovered two replication-competent VSV-based vaccines encoding the SARS-CoV-2 spike protein either alone (VSV-SARS2) or in combination with the EBOV GP (VSV-SARS2-EBOV). EB…
Audray Harris · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $5,807 — Coronaviruses remain both a seasonal health burden and pandemic threat due to the antigenic variation of viral glycoproteins and the ability of animal coronaviruses to cause zoonotic infections in humans. Although conserved epitopes have been identified, there is a fundamental gap in understanding a…
Susan Amara · NATIONAL INSTITUTE OF MENTAL HEALTH · 2023 · $1,496,655 — 1) Production of rodent transgenics Mouse transgenic production projects: 12 Rat transgenic production projects: 2 Cryopreservation projects: 35 Rederivation projects: 23 2) SARS-Cov2 Fibroblast cultures have been propagated using methods developed in the lab (see below) over several years. These c…
Carole Bewley · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2023 · $947,627 — The long term goals and objectives of our project "Inhibitors and Probes of HIV-1 Cell Fusion" are to identify and engineer protein and small molecule therapeutics, probes and vaccine immunogens that can be translated for the treatment and long acting inhibition of HIV/AIDS. Subprojects include desi…
Anton Simeonov · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2023 · $125,849 — The antibody discovery project harnesses the therapeutic potential of small biologicals known as nanobodies. By constructing a humanized llama phage display library for use here at NCATS, it is possible to screen for therapeutically relevant nanobodies as needed. The small size of nanobodies makes t…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $101,616 — Following the success of our HIV-1 vaccine platform based on co-formulated Env+Gag mRNA in order to produce non-infectious VLPs (Zhang et al., Nat. Med. 27:2234, 2021), in collaboration with Moderna, Inc., we have designed a similar vaccine platform for SARS-CoV-2. The major results obtained thus fa…
JOSHUA ZIMMERBERG · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · 2023 · $1,395,355 — In the first paper reporting this discovery, a study of the membrane mechanisms by which the influenza virus can disrupt a target membrane, we establish that FPs underly this disruption: in target membranes, a reversible pore forms upon addition of FP in the absence of virus or even the rest of HA. …
Steven Holland · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $2,783,766 — The major activities of this research project in the past have centered around using our optimized methods and procedures for imaging rhesus macaques, NZW rabbits, and common marmosets on PET/CT scanners while conducting a variety of chemotherapy and basic immunology experiments in Mtb models. We ha…
Tongqing Zhou · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $245,592 — The continued emergence of SARS-CoV-2 Omicron sub-variants evaded neutralization by antibodies elicited against the viral spike protein of early variants. To map or evaluate the antibody responses and antibody repertoire elicited by current vaccines or infection, we developed molecular probes based …
Michel C Nussenzweig · ROCKEFELLER UNIVERSITY · 2023 · $983,100 — Project Summary The COVID-19 pandemic is currently gripping the world. Aside from the health consequences, the necessary decrease in human activity has resulted in economic losses without modern precedent, especially in the developing world where health care and sanitation were not sufficient even …
Viviana A Simon · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $1,041,898 — The SARS-CoV-2 pandemic represents an exceptional public health crisis highlighting the need for better understanding of the mechanisms controlling broadly protective immune responses and generating vaccine candidates able to elicit such responses. The program project entitled “Programming Long-last…
YOSHIHIRO KAWAOKA · UNIVERSITY OF WISCONSIN-MADISON · 2023 · $2,819,456 — SUMMARY As part of the Pan-Coronavirus Vaccine (PanCoVac) Consortium, the goal of Research Project 1 (RP1) is the ‘Design and evaluation of pan-CoV vaccines’. A comprehensive characterization of the B and T cell responses to vaccination will be carried out by Research Project 2 (RP2, ‘Immunological…
Charles M Rice · ROCKEFELLER UNIVERSITY · 2023 · $983,100 — Project Summary – BSL3 Virology and Animal Models Core The COVID-19 pandemic has disrupted all aspects of society across the globe. The overarching theme of this P01 proposal is to study immune responses to infection with SARS-CoV-2 and their reactivity against other coronaviruses (CoVs) such that i…
Paul D. Bieniasz · ROCKEFELLER UNIVERSITY · 2023 · $983,100 — ABSTRACT-PROJECT 2 The SARS-CoV-2 pandemic has established beyond doubt that animal coronaviruses are a major potential threat to human health. Although vaccines and antibodies to prevent and treat SARS-CoV-2 infection have been developed at unprecedented speed, the recurrent emergence of coronavir…
Erica Ollmann Saphire · BRIGHAM AND WOMEN'S HOSPITAL · 2023 · $2,060,891 — Project 3 Summary Coronaviruses will likely remain a persistent threat to human health. However, whether the next significant disease outbreak will be caused by a known coronavirus, another novel coronavirus, or continued surges from variant(s) of SARS-CoV-2 is unknown. The goal of this project is t…
DANA P ASCHERMAN · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2023 · $209,880 — The current SARS-CoV-2 pandemic has had devastating consequences, with more than 110,000,000 cases and 2,400,000 deaths worldwide. Beyond the direct effects of SARS-CoV-2 infection, much of the morbidity and mortality stems from dysregulated activation of the immune system that culminates in systemi…
Ali Hassan Ellebedy · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $2,506,857 — The SARS-CoV-2 pandemic represents an exceptional public health crisis highlighting the need for better understanding of the mechanisms controlling broadly protective immune responses and generating vaccine candidates able to elicit such responses. The program project entitled “Programming Long-last…
Jack H Freed · CORNELL UNIVERSITY · 2023 · $410,000 — For many years Freed has pioneered the development of electron-spin resonance (ESR) methods for the study of proteins and their dynamical effects on membranes. The goal of this proposal is to use those ESR techniques to advance our knowledge of 1) viral membrane fusion and 2) Intrinsic Disordered Pr…
Rebecca Michelle DuBois · UNIVERSITY OF CALIFORNIA SANTA CRUZ · 2023 · $350,421 — PROJECT SUMMARY Human astroviruses (HAstV) are a leading cause of viral diarrhea in children. Divergent HAstV strains are associated with fatal human encephalitis. Currently, no vaccines or antiviral therapies exist for HAstV infections. Our goal is to identify sites of vulnerability (Achilles' heel…